The kinase inhibitor DMAT reduces experimental HCC growth in mice
G Sass, H Sirma, S Hashemolhosseini, C Hellerbrand, D Neureiter, M Ocker, G Tiegs · Zeitschrift für Gastroenterologie · 2011 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background and Aims: Currently, the most promising strategy to prolong survival of patients with the diagnosis of primary HCC is the use of the multi kinase inhibitor Sorafenib. We now investigated benefits of the serin/threonine kinase inhibitor 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), which inhibits activity of CK2, PDK1, PIM-1 and PIM-3 at almost equimolar IC50. We investigated hepatoma cell survival and experimental HCC growth and compared mechanisms of DMAT and Sorafenib action. Methods: Viability and apoptosis following DMAT incubation were measured in the human hepatoma cell lines HepG2…
